GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Minority Interest

Oncodesign Precision Medicine (XPAR:ALOPM) Minority Interest : €0.00 Mil (As of Jun. 2022)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Oncodesign Precision Medicine's minority interest for the quarter that ended in Jun. 2022 was €0.00 Mil.


Oncodesign Precision Medicine Minority Interest Historical Data

The historical data trend for Oncodesign Precision Medicine's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Minority Interest Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21
Minority Interest
- -

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22
Minority Interest - - -

Oncodesign Precision Medicine Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


Oncodesign Precision Medicine (XPAR:ALOPM) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine (XPAR:ALOPM) Headlines

No Headlines